-
NYSE New Highs: Merck & Co (NYSE:MRK), Public Service Enterprise Group (NYSE:PEG), American International Group (NYSE:AIG), Lorillard (NYSE:LO)
Merck & Co Inc (NYSE:MRK) is in the final stages of selling its consumer health unit for close to $14 billion, Reuters reported last week, as its market share in the sector is seen as sub-scale compared with those of market leaders. Shares of Merck & Co., Inc. (NYSE:MRK) closed at $58.56 in last trading…
-
Drug Most Active Stock: Pfizer (NYSE:PFE), Merck & Co (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Eli Lilly (NYSE:LLY)
Bristol-Myers Squibb Co. and Pfizer Inc. (NYSE:PFE) announced results of a pre-specified sub analysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).…
-
Healthcare most active stocks: Pfizer Inc. (NYSE:PFE), Rexahn Pharmaceuticals (NYSEMKT: RNN), Merck & Co (NYSE:MRK), Ariad Pharmaceuticals (NASDAQ:ARIA)
Pfizer Inc. (NYSE:PFE) has updated its FY14 earnings guidance. The company provided earnings per share (EPS) guidance of $2.20-2.30 for the period, compared to the Thomson Reuters consensus estimate of $2.29, Stock Ratings Network.com reports. The company issued revenue guidance of $49.2-51.2 billion, compared to the consensus revenue estimate of $49.75 billion. Shares of Pfizer…
-
Healthcare Most Active – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Trading of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) options resulted in establishing a new 90-day call volume record, where 32,467 call contracts exchanged hands between the buyers and the sellers. A total of 9,242 put and 32,467 call contracts was traded raising a 0.28 put/call ratio on shares of ARIA. Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) closed…
-
Health Stocks – Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Eli Lilly & Co. (NYSE:LLY), Sanofi SA (ADR) (NYSE:SNY)
Top gainer for 2014 was drug giant Pfizer Inc. (NYSE:PFE) after returning 26% in 2013, with an expected gain of almost 8%. Pfizer has been restructuring, it has the same patent cliff of other pharma stocks, and its prospects ahead are not likely full of major growth metrics. Shares of Pfizer Inc. (NYSE:PFE) closed at…
-
Drug Sector Most Active Stock – Pfizer (NYSE:PFE), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ)
Pfizer Inc. (NYSE:PFE),one of the largest pharmaceutical companies in the world, participated in the Pioneering, Efficiency, Diversity and Distinctiveness Forum, which was held recently in Riyadh with the support of Labor Minister Adel Fakeih. Shares of Pfizer Inc. (NYSE:PFE) closed at $30.64 in last trading session. Yesterday share price of the company was traded in…
-
Hot Stocks – AT&T Inc. (T), Pfizer Inc. (PFE), Merck & Co. (MRK), QUALCOMM (QCOM)
Jefferies Group started coverage on shares of AT&T Inc. (NYSE:T) in a research note released on Thursday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $40.00 target price on AT&T Inc. (NYSE:T) stock. Shares of AT&T Inc. (NYSE:T) closed at $ 34.95 during last trading session. The share price of the company…
-
Health Stocks – Merck & Co. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), Bristol-Myers Squib (NYSE:BMY), Johnson & Johnson (NYSE:JNJ)
Merck & Co., Inc. (NYSE:MRK) said it will begin twolate-stage trials of its experimental Alzheimer’s drug, one of the industry’s best hopes for slowing the memory-robbingdisease, after an independent monitoring board reviewed itssafety and recommended that more patients be recruited forstudies. Shares of Merck & Co., Inc. (NYSE:MRK) closed at $ 49.32 during last trading…
-
Drug Maker In Pressure: Merck & Co., Inc. (NYSE:MRK) Face Lawsuit of $100 million
A sales person for Merck & Co., Inc. (NYSE:MRK) filed court case of overi$100M sex discrimination against the drugmaker, asserting that it mainly distinguishes alongside pregnant employees and women among children. In a claim filed in U.S. District Court in New Jersey, the claimant, Kelli Smith asserts she was downgraded for taking maternity leave in…
-
Merck & Co., Inc. (NYSE:MRK) to Appoint Roger Perlmutter Research Head, Barclays PLC (ADR) (NYSE:BCS) Upgraded the Company to Buy
The renowned pharmaceutical firm Merck & Co., Inc. (NYSE:MRK) recently declared that it is appointing the Amgen retired research chief at its own research division. The division is currently being headed by Peter Kim and after his planned retirement Roger Perlmutter will take his position at Merck. Some of the most successful products of Merck…